YL 0066B
Alternative Names: YL-0066BLatest Information Update: 12 Jan 2022
At a glance
- Originator Shenzhen Ionova Life Sciences Co., Ltd.
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Jan 2022 Preclinical trials in Solid tumours in China (unspecified route) (Shenzhen Ionova Life Sciences pipeline, January 2022)